Volume 11 Issue 2
Mar.  2020
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(2): 293-297, 310
Ji Yanping, Sun Zimin. Treatment progress of severe aplastic anemia[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 293-297, 310. doi: 10.3969/j.issn.1674-7445.2020.02.018
Citation: Ji Yanping, Sun Zimin. Treatment progress of severe aplastic anemia[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 293-297, 310. doi: 10.3969/j.issn.1674-7445.2020.02.018
shu

Treatment progress of severe aplastic anemia

doi: 10.3969/j.issn.1674-7445.2020.02.018

  • Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China

More Information
  • Corresponding author: Sun Zimin, Email: zmsun_vip@163.com
  • Received Date: 2019-12-23
    Available Online: 2021-01-19
  • Publish Date: 2020-03-15
    Abstract
  • Severe aplastic anemia (SAA) is a rare type of bone marrow hematopoietic failure, which is associated with toxic T lymphocyte-based immune dysfunction, abnormal hematopoietic microenvironment and damage of hematopoietic stem cells in patients. SAA characterized by acute onset, rapid progression and high mortality rate, which requires rapid and stable recovery of the patients' hematopoietic function. In this article, the therapeutic progresses on immunosuppressive therapy (IST), sibling human leukocyte antigen (HLA)-matched allogenetic hematopoietic stem cell transplantation (allo-HSCT), replacement of donor hematopoietic stem cell transplantation and unrelated umbilical cord blood hematopoietic stem cell transplantation (UCBT) for SAA were reviewed.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    HOSOKAWA K, MURANSKI P, FENG X, et al. Memory stem T cells in autoimmune disease: high frequency of circulating CD8+ memory stem cells in acquired aplastic anemia[J]. J Immunol, 2016, 196(4):1568-1578. DOI: 10.4049/jimmunol.1501739.
    [2]
    KILLICK SB, BOWN N, CAVENAGH J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia[J]. Br J Haematol, 2016, 172(2):187-207. DOI: 10.1111/bjh.13853.
    [3]
    聂玲辉, 伍志勇, 朱晓光, 等.重型再生障碍性贫血的研究进展[J].分子影像学杂志, 2017, 40(1):85-89. DOI: 10.3969/j.issn.1674-4500.2017.01.25.

    NIE LH, WU ZY, ZHU XG, et al. Research progress of severe aplastic anemia[J]. J Mol Imaging, 2017, 40(1):85-89. DOI: 10.3969/j.issn.1674-4500.2017.01.25.
    [4]
    MEDINGER M, DREXLER B, LENGERKE C, et al. Pathogenesis of acquired aplastic anemia and the role of the bone marrow microenvironment[J]. Front Oncol, 2018, 8:587. DOI: 10.3389/fonc.2018.00587.
    [5]
    苏雁.重型再生障碍性贫血的非移植治疗进展[J].中国小儿血液与肿瘤杂志, 2017, 22(4):169-172.DOI:10. 3969/j.issn.1673-5323.2017.04.001.

    SU Y. Research progress of non-transplantation treatments of severe aplastic anemia[J]. J Chin Pediatr Blood Cancer, 2017, 22(4):169-172. DOI:10.3969/j.issn. 1673-5323.2017.04.001.
    [6]
    叶蕾, 井丽萍, 杨文睿, 等.围免疫抑制治疗期感染对重型再生障碍性贫血患者血液学反应及生存的影响[J].中华血液学杂志, 2015, 36(8):670-675.DOI: 10.3760/cma.j.issn.0253-2727.2015.08.009.

    YE L, JING LP, YANG WR, et al. Effects of peri-immunosupressive therapy period infection on hematologic response and survival of severe aplastic[J]. Chin J Hematol, 2015, 36(8):670-675. DOI: 10.3760/cma.j.issn.0253-2727.2015.08.009.
    [7]
    PIERRI F, DUFOUR C. Management of aplastic anemia after failure of frontline immunosuppression[J]. Expert Rev Hematol, 2019, 12(10):809-819. DOI: 10.1080/17474086.2019.1645003.
    [8]
    BUSSEL J, KULASEKARARAJ A, COOPER N, et al. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists[J]. Semin Hematol, 2019, 56(4):262-278. DOI: 10.1053/j.seminhematol.2019.09.001.
    [9]
    SANZ J, MOSCARDÓ F, MONTORO J, et al. Partial T cell-depleted peripheral blood stem cell transplantation from HLA-identical siblingdonors for patients with severe aplastic anemia[J]. Biol Blood Marrow Transplant, 2020, 26(1):83-87. DOI: 10.1016/j.bbmt.2019.08.020.
    [10]
    MARSH JCW, RISITANO AM, MUFTI GJ. The case for upfront HLA-matched unrelated donor hematopoietic stem cell transplantation as a curative option for adult acquired severe aplastic anemia[J]. Biol Blood Marrow Transplant, 2019, 25(9):e277-e284. DOI: 10.1016/j.bbmt. 2019.05.012.
    [11]
    YANG S, YUAN X, MA R, et al. Comparison of outcomes of frontline immunosuppressive therapy and frontline haploidentical hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched sibling donor[J]. Biol Blood Marrow Transplant, 2019, 25(5):975-980. DOI: 10.1016/j.bbmt.2019.01.017.
    [12]
    FATOBENE G, STORER BE, SALIT RB, et al. Disability related to chronic graft-versus-host disease after alternative donor hematopoietic celltransplantation[J]. Haematologica, 2019, 104(4):835-843. DOI: 10.3324/haematol.2018.202754.
    [13]
    OLNES MJ, SCHEINBERG P, CALVO KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia[J]. N Engl J Med, 2012, 367(1):11-19. DOI: 10.1056/NEJMoa1200931.
    [14]
    TOWNSLEY DM, SCHEINBERG P, WINKLER T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia[J]. N Engl J Med, 2017, 376(16):1540-1550. DOI: 10.1056/NEJMoa1613878.
    [15]
    DE BRUIN AM, VOERMANS C, NOLTE MA. Impact of interferon-γ on hematopoiesis[J]. Blood, 2014, 124(16):2479-2486. DOI: 10.1182/blood-2014-04-568451.
    [16]
    杨世伟, 马荣军, 赵娟娟, 等.不同方式异基因造血干细胞移植一线治疗儿童及青少年重型再生障碍性贫血的比较[J].中华血液学杂志, 2018, 39(3):184-189. DOI: 10.3760/cma.j.issn.0253-2727.2018.03.003.

    YANG SW, MA RJ, ZHAO JJ, et al. Comparison of different styles of allogeneic hematopoietic stem cell transplantation as first-line treatment treated with severe aplastic anemia in children and adolescents[J]. Chin J Hematol, 2018, 39(3):184-189. DOI: 10.3760/cma.j.issn.0253-2727.2018.03.003.
    [17]
    XU LP, JIN S, WANG SQ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant[J]. J Hematol Oncol, 2017, 10(1):10-25. DOI: 10.1186/s13045-017-0398-y.
    [18]
    DEZERN AE, ZAHURAK M, SYMONS H, et al. Alternative donor transplantation with high-dosepost-transplantation cyclophosphamide for refractory severe aplastic anemia[J]. Biol Blood Marrow Transplant, 2017, 23(3):498-504. DOI: 10.1016/j.bbmt.2016.12.628.
    [19]
    LIU HL, SUN ZM, GENG LQ, et al. Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival[J]. Bone Marrow Transplant, 2012, 47(9):1186-1190. DOI: 10.1038/bmt.2011.251.
    [20]
    MOALIC-ALLAIN V. Medical and ethical considerations on hematopoietic stem cells mobilization for healthy donors[J]. Transfus Clin Biol, 2018, 25(2):136-143. DOI: 10.1016/j.tracli.2018.02.004.
    [21]
    PEFFAULT DE LATOUR R, CHEVRET S, JUBERT C, et al. Unrelated cord blood transplantation in patients with acquired refractory aplastic anemia: a nationwide phase Ⅱ study[J]. Blood, 2018, 132(7):750-754. DOI: 10.1182/blood-2018-01-829630.
    [22]
    PEFFAULT DE LATOUR R, PURTILL D, RUGGERI A, et al. Influence of nucleated cell dose on overall survival ofunrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation[J]. Biol Blood Marrow Transplant, 2011, 17(1):78-85. DOI: 10.1016/j.bbmt.2010.06.011.
    [23]
    PEFFAULT DE LATOUR R. Transplantation for bone marrow failure: current issues[J]. Hematology Am Soc Hematol Educ Program, 2016(1):90-98. DOI: 10.1182/asheducation-2016.1.90.
    [24]
    CLÉ DV, ATTA EH, DIAS DSP, et al. Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study[J]. Ann Hematol, 2018, 97(11):2039-2046. DOI: 10.1007/s00277-018-3416-4.
    [25]
    ZENG Y, WANG S, WANG J, et al. Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem celltransplantation: a large-sample study from China[J]. Sci Rep, 2018, 8(1):2479. DOI: 10.1038/s41598-018-20853-9.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (425) PDF downloads(40) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return